Is ZLAB or STTK more profitable?

Shattuck Labs has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% Shattuck Labs N/A -60.73% -55.75%

Does the media prefer ZLAB or STTK?

In the previous week, Zai Lab had 1 more articles in the media than Shattuck Labs. MarketBeat recorded 6 mentions for Zai Lab and 5 mentions for Shattuck Labs. Zai Lab's average media sentiment score of 0.95 beat Shattuck Labs' score of 0.45 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to STTK or ADMA?

In the previous week, ADMA Biologics had 34 more articles in the media than Shattuck Labs. MarketBeat recorded 39 mentions for ADMA Biologics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.45 beat ADMA Biologics' score of 0.12 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 35 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to STTK or SRPT?

In the previous week, Sarepta Therapeutics had 15 more articles in the media than Shattuck Labs. MarketBeat recorded 20 mentions for Sarepta Therapeutics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.45 beat Sarepta Therapeutics' score of 0.05 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Is STTK or PVLA more profitable?

Palvella Therapeutics' return on equity of -56.87% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Palvella Therapeutics N/A -56.87% -42.50%

Does the media favor STTK or PVLA?

In the previous week, Shattuck Labs had 1 more articles in the media than Palvella Therapeutics. MarketBeat recorded 5 mentions for Shattuck Labs and 4 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.45 beat Shattuck Labs' score of 0.45 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Shattuck Labs (STTK) Competitors

$6.43 -0.21 (-3.16%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$6.42 0.00 (-0.08%)

As of 06:35 AM Eastern

Compare

STTK vs. HRMY, ZLAB, ADMA, SRPT, and PVLA

Should you buy Shattuck Labs stock or one of its competitors? MarketBeat compares Shattuck Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shattuck Labs include Harmony Biosciences (HRMY), Zai Lab (ZLAB), ADMA Biologics (ADMA), Sarepta Therapeutics (SRPT), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry.

How does Shattuck Labs compare to Harmony Biosciences?

Shattuck Labs (NASDAQ:STTK) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

In the previous week, Shattuck Labs had 4 more articles in the media than Harmony Biosciences. MarketBeat recorded 5 mentions for Shattuck Labs and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.91 beat Shattuck Labs' score of 0.45 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Harmony Biosciences	Very Positive

Harmony Biosciences has a net margin of 16.20% compared to Shattuck Labs' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Harmony Biosciences	16.20%	17.19%	11.99%

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Harmony Biosciences has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	493.05	-$48.81M	-$0.63	N/A
Harmony Biosciences	$868.45M	2.37	$158.69M	$2.48	14.33

Shattuck Labs has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Shattuck Labs presently has a consensus target price of $11.00, indicating a potential upside of 71.07%. Harmony Biosciences has a consensus target price of $42.50, indicating a potential upside of 19.58%. Given Shattuck Labs' stronger consensus rating and higher possible upside, research analysts clearly believe Shattuck Labs is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

Harmony Biosciences beats Shattuck Labs on 10 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Shattuck Labs (NASDAQ:STTK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, Zai Lab had 1 more articles in the media than Shattuck Labs. MarketBeat recorded 6 mentions for Zai Lab and 5 mentions for Shattuck Labs. Zai Lab's average media sentiment score of 0.95 beat Shattuck Labs' score of 0.45 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 8.8% of Shattuck Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Shattuck Labs has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Shattuck Labs	N/A	-60.73%	-55.75%

Zai Lab has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Zai Lab currently has a consensus target price of $40.00, suggesting a potential upside of 103.87%. Shattuck Labs has a consensus target price of $11.00, suggesting a potential upside of 71.07%. Given Zai Lab's higher probable upside, equities research analysts plainly believe Zai Lab is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Shattuck Labs has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.85	-$175.54M	-$1.62	N/A
Shattuck Labs	$1M	493.05	-$48.81M	-$0.63	N/A

Summary

Shattuck Labs beats Zai Lab on 10 of the 17 factors compared between the two stocks.

How does Shattuck Labs compare to ADMA Biologics?

Shattuck Labs (NASDAQ:STTK) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, ADMA Biologics had 34 more articles in the media than Shattuck Labs. MarketBeat recorded 39 mentions for ADMA Biologics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.45 beat ADMA Biologics' score of 0.12 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	35 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ADMA Biologics has a net margin of 32.43% compared to Shattuck Labs' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
ADMA Biologics	32.43%	39.98%	28.08%

Shattuck Labs currently has a consensus target price of $11.00, indicating a potential upside of 71.07%. ADMA Biologics has a consensus target price of $19.67, indicating a potential upside of 119.25%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Shattuck Labs has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	493.05	-$48.81M	-$0.63	N/A
ADMA Biologics	$510.17M	4.08	$146.93M	$0.68	13.19

Summary

ADMA Biologics beats Shattuck Labs on 10 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Sarepta Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Shattuck Labs currently has a consensus price target of $11.00, suggesting a potential upside of 71.07%. Sarepta Therapeutics has a consensus price target of $25.09, suggesting a potential upside of 33.32%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities research analysts clearly believe Shattuck Labs is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sarepta Therapeutics	7 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Sarepta Therapeutics had 15 more articles in the media than Shattuck Labs. MarketBeat recorded 20 mentions for Sarepta Therapeutics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.45 beat Sarepta Therapeutics' score of 0.05 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Shattuck Labs has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Shattuck Labs has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	493.05	-$48.81M	-$0.63	N/A
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A

Shattuck Labs has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Summary

Shattuck Labs beats Sarepta Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Palvella Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, Shattuck Labs had 1 more articles in the media than Palvella Therapeutics. MarketBeat recorded 5 mentions for Shattuck Labs and 4 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.45 beat Shattuck Labs' score of 0.45 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

Palvella Therapeutics' return on equity of -56.87% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Palvella Therapeutics	N/A	-56.87%	-42.50%

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Shattuck Labs currently has a consensus price target of $11.00, indicating a potential upside of 71.07%. Palvella Therapeutics has a consensus price target of $199.53, indicating a potential upside of 36.64%. Given Shattuck Labs' higher probable upside, equities research analysts clearly believe Shattuck Labs is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Palvella Therapeutics has higher revenue and earnings than Shattuck Labs. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	493.05	-$48.81M	-$0.63	N/A
Palvella Therapeutics	$42.81M	48.92	-$41.72M	-$4.17	N/A

Summary

Palvella Therapeutics beats Shattuck Labs on 9 of the 16 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$509.16M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-10.21	20.85	27.11	24.26
Price / Sales	493.05	314.01	589.18	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	4.95	8.49	10.73	6.29
Net Income	-$48.81M	$23.83M	$3.58B	$330.66M
7 Day Performance	-11.43%	-3.56%	-2.11%	-1.35%
1 Month Performance	30.16%	6.31%	3.27%	-0.64%
1 Year Performance	684.15%	48.30%	26.32%	19.08%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	3.5406 of 5 stars	$6.43 -3.2%	$11.00 +71.1%	+688.5%	$509.16M	$1M	N/A	100
HRMY Harmony Biosciences	4.7556 of 5 stars	$38.26 +3.4%	$41.44 +8.3%	+4.5%	$2.21B	$868.45M	15.43	200	Positive News
ZLAB Zai Lab	2.5671 of 5 stars	$19.35 +1.4%	$40.00 +106.7%	-40.1%	$2.19B	$460.16M	N/A	1,784
ADMA ADMA Biologics	4.4711 of 5 stars	$9.21 +0.5%	$19.67 +113.5%	-51.5%	$2.13B	$510.17M	13.54	530	Trending News
SRPT Sarepta Therapeutics	2.9206 of 5 stars	$19.79 +3.2%	$24.81 +25.4%	+3.6%	$2.09B	$2.20B	N/A	1,372

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. HRMY, ZLAB, ADMA, SRPT, and PVLA

How does Shattuck Labs compare to Harmony Biosciences?

Summary

How does Shattuck Labs compare to Zai Lab?

Summary

How does Shattuck Labs compare to ADMA Biologics?

Summary

How does Shattuck Labs compare to Sarepta Therapeutics?

Summary

How does Shattuck Labs compare to Palvella Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. HRMY, ZLAB, ADMA, SRPT, and PVLA

How does Shattuck Labs compare to Harmony Biosciences?

Does the media favor STTK or HRMY?

Is STTK or HRMY more profitable?

Do institutionals & insiders have more ownership in STTK or HRMY?

Which has higher earnings and valuation, STTK or HRMY?

Which has more volatility and risk, STTK or HRMY?

Do analysts prefer STTK or HRMY?

Summary

How does Shattuck Labs compare to Zai Lab?

Does the media prefer ZLAB or STTK?

Do institutionals and insiders hold more shares of ZLAB or STTK?

Is ZLAB or STTK more profitable?

Which has more risk and volatility, ZLAB or STTK?

Do analysts prefer ZLAB or STTK?

Which has better valuation & earnings, ZLAB or STTK?

Summary

How does Shattuck Labs compare to ADMA Biologics?

Does the media refer more to STTK or ADMA?

Do institutionals & insiders have more ownership in STTK or ADMA?

Is STTK or ADMA more profitable?

Do analysts prefer STTK or ADMA?

Which has more volatility and risk, STTK or ADMA?

Which has better valuation & earnings, STTK or ADMA?

Summary

How does Shattuck Labs compare to Sarepta Therapeutics?

Do analysts recommend STTK or SRPT?

Does the media refer more to STTK or SRPT?

Is STTK or SRPT more profitable?

Do insiders and institutionals hold more shares of STTK or SRPT?

Which has higher earnings and valuation, STTK or SRPT?

Which has more risk & volatility, STTK or SRPT?

Summary

How does Shattuck Labs compare to Palvella Therapeutics?

Does the media favor STTK or PVLA?

Which has more risk & volatility, STTK or PVLA?

Is STTK or PVLA more profitable?

Do insiders & institutionals have more ownership in STTK or PVLA?

Do analysts rate STTK or PVLA?

Which has preferable earnings & valuation, STTK or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools